A Pilot Study of Urokinase-Type Plasminogen Activator (uPA) Overexpression in the Brush Cytology of Patients with Malignant Pancreatic or Biliary Strictures

<table>Immunohistochemistry using uPA antibody.  Positive staining of cholangiocarcinoma cells from cytologic brushings obtained during ERCP (arrows).</table>

HPB Surgery

fig2

Figure 2

Figure 2: A Pilot Study of Urokinase-Type Plasminogen Activator (uPA) Overexpression in the Brush Cytology of Patients with Malignant Pancreatic or Biliary Strictures 

Figure 2 | A Pilot Study of Urokinase-Type Plasminogen Activator (uPA) Overexpression in the Brush Cytology of Patients with Malignant Pancreatic or Biliary Strictures 